|
Post by mnkdfann on Jan 20, 2020 15:07:29 GMT -5
I know this is not the correct thread, however, it sure seemed odd to me that the MM's let the options finish in the money Friday without a fight? I don't recall that happening in recent memory. Corrections welcome. I thought "IN THE MONEY" was the strike price plus the premium? Does that mean you bought your $1.50 options for $ .01 each?? Doubt that.... Did he say they were $1.50 options? Maybe they had a lower strike price. Anyway, in the money means the strike price is less than the share price. Even then, you may have a loss depending on the price you paid for the option. www.investopedia.com/terms/i/inthemoney.asp" It is important to note that ITM doesn't mean the trader is making money. When buying an ITM option, the trader will need the option's value to move farther into the money to make a profit. In other words, investors buying call options need the stock price to climb high enough so that it at least covers the cost of the option's premium."
|
|
|
Post by mnkdfann on Jan 20, 2020 12:32:49 GMT -5
|
|
|
Post by mnkdfann on Jan 20, 2020 8:53:31 GMT -5
Speaking of options it appears a crap load of mine got exercised Friday. Anyone lose their shares out there, looks like I found them. Lets Go! You sound surprised? If you owned the calls and called away someone's shares, either you exercised the options early or they were exercised on expiry. Either way, it shouldn't have been a surprise to you.
|
|
|
Post by mnkdfann on Jan 19, 2020 16:08:22 GMT -5
Aren’t they more likely to short because they can’t use puts? ..just like people are more likely to buy shares if they can’t buy calls. If they can’t “hedge” their short, they’re are less likely to short. Hedge being the key here, not short. They CAN hedge their short using MNKD options. Lots of MNKD options (2020 and 2021) are available. If you heard otherwise, you were misinformed.
|
|
|
Post by mnkdfann on Jan 19, 2020 16:05:59 GMT -5
I'm no expert, but I would think the 2020 and 2021 options available would be more than enough. Why would they want to hedge using expensive 2022 LEAPS? Ok, I’m no options player, (yet), but the chatter here in mnkd land, is that the 2020 options are MIA. I expected to see them after 2019 OPEX but those who play options say they aren’t there. All other companies options are front and center, mnkd,,,, nothing as of Saturday. No, the 2020 and 2021 options ARE available. The 2022 LEAPS are missing. But as has been pointed out, they are missing for lots of different companies. Not just for Mannkind. People who want to hedge can do so with the MNKD 2020 and 2021 options which (again) ARE available.
|
|
|
Post by mnkdfann on Jan 19, 2020 11:19:03 GMT -5
How much activity is there for the 2021 options? MM like money so my guess is it has to do with demand or lack there of. Logical, and likely true, someone at ST brought up that the lack of options = problematic to hedge short. I thought that was an interesting comment. My point being, if no options maybe less likely to short. I'm no expert, but I would think the 2020 and 2021 options available would be more than enough. Why would they want to hedge using expensive 2022 LEAPS?
|
|
|
Post by mnkdfann on Jan 18, 2020 19:13:12 GMT -5
radgray68.... Do you know why there are no 2022 options listed they usually come out in October. Or anyone? I don't know, but there are lots of companies much larger than MNKD with the same thing. E.g. DDOG, PSNL, PTLA, to name just 3 from among the stocks I follow. I suspect it means nothing, really. Nothing significant, I mean.
|
|
|
Post by mnkdfann on Jan 17, 2020 1:03:58 GMT -5
I didn’t see a link to the post. I suspect that may have been edited. The naive assumptions do look like something I might have posted 5 years ago on Yahoo! Message Boards. Some of the wording doesn’t look like me. I can’t remember saying toolbags but maybe I did. I used to be a lot more vehement about the shorting. Now I just look at it like part of life. You know, like terrorists and theives. Now, truth be told, I get that shorting is a legal and legimitate way to make money using a “hedge” strategy, but honestly I think anymore it is used to destroy value for the benefit of the short. I would be heartily in favor of a market that did not permit shorting. I am curious if many companies would be willing to list there. SOX caused many companies to go private and to de-list. Did the rise of “hedge” funds contribute to that too? Don’t know. But as to whether I wrote that post or not. Maybe I did. Not everything I write is good. Same for bababooey. :-) How does shorting destroy a company? It's just savvy investors who are taking advantage of a falling stock. Good companies don't fail due to short selling. A company's stock price is dictated by it's success. It's quite naive to think that all stocks should go up, no matter what. The cold hard truth is that Mannkind is/was a company with a MASSIVE amount of debt and a single product that just doesn't sell. Its kinda silly to expect a stock price to be high when the company is doing so poorly. This is where confirmation bias has lead you and many others to make very poor decisions. It's clear any negative opinion is not welcome here... I read that Tesla is the most shorted stock there is, yet that hasn't held it back. Prior to that, it was Apple. markets.businessinsider.com/news/stocks/tesla-stock-most-shorted-us-beats-apple-highest-short-interest-2020-1-1028823046
|
|
|
Post by mnkdfann on Jan 16, 2020 21:37:10 GMT -5
In 2019, you (they) say?
|
|
|
Post by mnkdfann on Jan 16, 2020 14:13:33 GMT -5
From Brazilian Instagram: www.picuki.com/tag/dassettepharmaAlthough the post does not explicitly state as such, one would believe that Afrezza is actually for sale at Dassette Pharma, whose philosophy is "It's good to do well". Looks like Biomm is moving with Afrezza as they stated last week! INHALABLE INSULIN COMES TO DASSETTE PHARMA ⠀ We just received AFREZZA, fast-acting inhalation insulin. The product is indicated to improve glycemic control in adult patients with diabetes. Its main advantage is to dispense with the use of needles, bringing more comfort and quality of life. It is the first inhaled insulin approved by Anvisa in Brazil. According to the manufacturer, the product can prevent the use of up to 1000 injections per year. ✅How to use? Insulin comes in powder form and must be inhaled with the aid of an inhaler before meals. Insulin reaches the lung quickly and in less than 1 minute it is already in the bloodstream, where it works by lowering sugar levels. ⠀ ✅Who can use? Patients with type 1 and type 2 diabetes who need fast-acting insulin. Talk to your doctor to find out if the product can be used in your treatment ⠀ ✅Afrezza replaces basal (long-lasting) insulin? No. It must be used in combination with long-acting insulin. ⠀ ✅How can I find the product? It is available in three presentations: -Afrrezza 8 wm with 90 refills and 2 inhalers -Afrezza 4 wm / 8 ui with 90 refills each and 2 inhalers -Afrezza 12 wm with 90 refills and 2 inhalers ⠀ 📱Want to know more? Contact us by Whatsapp: (41) 99967-0516
|
|
|
Post by mnkdfann on Jan 16, 2020 10:07:44 GMT -5
Sanofi's former CEO, Brandicort, also said in a video/transcript I saw on Proboards, that Afrezza wouldn’t be commercially viable until 2020. I don’t remember any reasoning given, just the statement. Must be something magical about 2020. Was this back when Sanofi was still involved, and actively trying to make Afrezza commercially viable? (I suppose it almost must have been; why else would he comment.)
|
|
|
Post by mnkdfann on Jan 13, 2020 23:19:53 GMT -5
my point is that every company board that Hooper is put on gets bought out ..... Okay, I get it now. If news leaked and MNKD is rising because of a buyout, hmmm. From what I can find online, it appears both ONYX and Beigene got a 30% to 35% pop when AMGEN bought out / took a stake. Since January 3, MNKD ran from 1.25 to 1.62. A pop of 29.6%. How much more room to run? Guess we'll see.
|
|
|
Post by mnkdfann on Jan 13, 2020 23:03:43 GMT -5
Yeah, but that's a very old document from circa 2013, is it not? It appears to be, given the dates and content etc.
My question is whether he has now left Amgen. Some on-line evidence suggests as much.
|
|
|
Post by mnkdfann on Jan 13, 2020 22:50:38 GMT -5
Is it possible that Hooper is finally leaving Amgen? The announcement below made it sound as though he was only staying on there for a limited while. Perhaps his leaving now is why he suddenly joined two Board of Directors recently. www.amgen.com/media/news-releases/2018/07/amgen-announces-succession-plans-for-two-executive-officers/THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ In September 2018, Anthony C. Hooper, currently executive vice president of Global Commercial Operations, will retire from this role. Murdo Gordon, chief commercial officer of Bristol-Myers Squibb Company, has been named as executive vice president of Global Commercial Operations, effective Sept. 3, 2018. Gordon will report to Bradway. Hooper will also remain at Amgen for a period of time to facilitate the transition to Gordon.
|
|
|
Post by mnkdfann on Jan 13, 2020 22:37:09 GMT -5
|
|